Share this article
Share this article
NEW YORK and BASEL, Switzerland, April 23, 2021 /PRNewswire/ Aruvant Sciences ( Aruvant ), a private company focused on developing gene therapies for rare diseases, today announced the appointment of Meghan Kelton, executive director, human resources (HR), and E. Blair Clark-Schoeb, senior vice president, communications, to the Aruvant leadership team. Ms. Kelton s HR experience in gene therapy and Ms. Clark-Schoeb s public company and rare disease communications know-how will be critical as we take Aruvant to the next level, said Will Chou, M.D., chief executive officer of Aruvant. With the company in a growth phase, Ms. Kelton will focus on building out the technical, development and manufacturing functions and creating an inclusive environment needed to support an engaged workforce. Ms. Clark-Schoeb will lead our internal and external communications efforts, investor relations, media effort and work with the rare disease and sick
ChemoCentryx Inc (CCXI) Q4 2020 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Zai Lab Announces Financial Results for Second-half and Full-year 2020
March 01, 2021 07:00 ET | Source: Zai Lab Limited Zai Lab Limited Company to Host Conference Call and Webcast Today at 8:00 a.m. ET
SHANGHAI and SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, today reported financial results for the second half and full year of 2020, along with corporate updates.
“2020 was another year of great accomplishment for Zai Lab,” said Dr. Samantha Du, Founder, Chairperson and Chief Executive Officer of Zai Lab. “We successfully launched ZEJULA for both second-line and first-line ovarian cancer and Optune for glioblastoma in China. We submitted NDAs and were granted priority reviews by China’s National Medical Products Administration (NMPA) for both QINLOCK for advanced gastrointestinal stromal tumors (GIST) and NUZYRA for community-acquire
ChemoCentryx to Present at Two Upcoming Investor Conferences globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.